434 related articles for article (PubMed ID: 21981437)
1. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
[TBL] [Abstract][Full Text] [Related]
2. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
[TBL] [Abstract][Full Text] [Related]
3. Additional safety risk to exceptionally approved drugs in Europe?
Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; Eichler HG; de Graeff PA; Mol PG
Br J Clin Pharmacol; 2011 Sep; 72(3):490-9. PubMed ID: 21501215
[TBL] [Abstract][Full Text] [Related]
4. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
Beers E; Egberts TC; Leufkens HG; Jansen PA
Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
[TBL] [Abstract][Full Text] [Related]
5. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
6. Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
Pacurariu AC; Hoeve CE; Arlett P; Genov G; Slattery J; Sturkenboom MCJM; Straus SMJM
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):168-173. PubMed ID: 29278866
[TBL] [Abstract][Full Text] [Related]
7. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
8. Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands.
de Vries E; Denig P; de Vries ST; Monster TBM; Hugtenburg JG; Mol PGM
Drug Saf; 2020 Jul; 43(7):677-690. PubMed ID: 32212054
[TBL] [Abstract][Full Text] [Related]
9. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
[TBL] [Abstract][Full Text] [Related]
10. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
Zeitoun JD; Lefèvre JH; Downing N; Bergeron H; Ross JS
PLoS One; 2014; 9(10):e109100. PubMed ID: 25333986
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing safety-related regulatory actions on first-in-class drugs: A double-cohort study.
Ikeda J; Kaneko M; Narukawa M
J Clin Pharm Ther; 2020 Jun; 45(3):496-502. PubMed ID: 31846100
[TBL] [Abstract][Full Text] [Related]
12. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
[TBL] [Abstract][Full Text] [Related]
13. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
[TBL] [Abstract][Full Text] [Related]
14. Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF-α Inhibitors.
Minnema LA; Giezen TJ; Hoekman J; Egberts TCG; Leufkens HGM; Gardarsdottir H
Clin Pharmacol Ther; 2021 Jul; 110(1):123-131. PubMed ID: 33278830
[TBL] [Abstract][Full Text] [Related]
15. Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors.
Hoeve CE; de Vries E; Mol PGM; Sturkenboom MCJM; Straus SMJM
Drug Saf; 2021 Jan; 44(1):73-82. PubMed ID: 33355904
[TBL] [Abstract][Full Text] [Related]
16. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
Ikeda J; Kaneko M; Narukawa M
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
[TBL] [Abstract][Full Text] [Related]
17. Impact of safety-related regulatory action on clinical practice: a systematic review.
Piening S; Haaijer-Ruskamp FM; de Vries JT; van der Elst ME; de Graeff PA; Straus SM; Mol PG
Drug Saf; 2012 May; 35(5):373-85. PubMed ID: 22480319
[TBL] [Abstract][Full Text] [Related]
18. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
19. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
20. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
